X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1428) 1428
humans (1205) 1205
fluorenes - therapeutic use (856) 856
male (743) 743
female (682) 682
drug combinations (496) 496
antimalarials - therapeutic use (469) 469
artemisinins - therapeutic use (458) 458
ethanolamines - therapeutic use (456) 456
animals (429) 429
malaria (410) 410
adult (388) 388
malaria, falciparum - drug therapy (372) 372
middle aged (359) 359
treatment outcome (338) 338
child, preschool (306) 306
infectious diseases (306) 306
drug therapy, combination (298) 298
fluorenes - administration & dosage (278) 278
child (266) 266
antiviral agents - therapeutic use (263) 263
tropical medicine (255) 255
infant (244) 244
benzimidazoles - therapeutic use (242) 242
parasitic diseases (231) 231
research (230) 230
drug therapy (221) 221
hepatitis c, chronic - drug therapy (213) 213
pharmacology & pharmacy (213) 213
parasitology (211) 211
adolescent (210) 210
artemether-lumefantrine (205) 205
aged (199) 199
fluorenes - adverse effects (191) 191
ethanolamines - administration & dosage (184) 184
artemisinins - administration & dosage (183) 183
antimalarials - administration & dosage (182) 182
plasmodium falciparum (178) 178
fluorenes - pharmacology (177) 177
malaria - drug therapy (176) 176
plasmodium falciparum - drug effects (166) 166
children (164) 164
health aspects (160) 160
abridged index medicus (154) 154
analysis (154) 154
young adult (153) 153
efficacy (151) 151
uridine monophosphate - analogs & derivatives (148) 148
genotype (145) 145
antimalarials (144) 144
hepatitis c (142) 142
care and treatment (139) 139
fluorenes - chemistry (133) 133
artemether (132) 132
rats (132) 132
sofosbuvir (131) 131
time factors (131) 131
hepatitis c virus (130) 130
drug resistance (129) 129
hepacivirus - genetics (128) 128
plasmodium-falciparum malaria (128) 128
malaria, falciparum - parasitology (126) 126
sofosbuvir - therapeutic use (126) 126
antimalarials - adverse effects (120) 120
mice (120) 120
uridine monophosphate - therapeutic use (119) 119
artemisinins - adverse effects (116) 116
artesunate (111) 111
ethanolamines - adverse effects (110) 110
ribavirin (107) 107
lumefantrine (106) 106
public, environmental & occupational health (105) 105
infections (104) 104
ledipasvir (103) 103
microbiology (103) 103
safety (103) 103
hepatitis (99) 99
infectious and parasitic diseases (98) 98
parasites (98) 98
arctic medicine. tropical medicine (94) 94
ribavirin - therapeutic use (93) 93
amodiaquine - therapeutic use (92) 92
medicine, general & internal (92) 92
artemisinin (91) 91
drugs (91) 91
plasmodium falciparum - genetics (91) 91
fluorenes - pharmacokinetics (88) 88
sulfadoxine-pyrimethamine (88) 88
therapy (88) 88
gastroenterology & hepatology (87) 87
malaria, falciparum - epidemiology (87) 87
chloroquine (85) 85
antimalarials - pharmacology (83) 83
patients (83) 83
resistance (83) 83
interferon (81) 81
medical research (81) 81
medicine (81) 81
recurrence (81) 81
public health (80) 80
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1299) 1299
German (171) 171
French (19) 19
Russian (17) 17
Danish (15) 15
Chinese (10) 10
Turkish (5) 5
Czech (2) 2
Dutch (2) 2
Japanese (2) 2
Hungarian (1) 1
Italian (1) 1
Korean (1) 1
Romanian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Internal Medicine, ISSN 0003-4819, 03/2015, Volume 162, Issue 6, pp. 407 - 419
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 20, pp. 1879 - 1888
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 20, pp. 1889 - 1898
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9973, pp. 1107 - 1113
Journal Article
Gastroenterology, ISSN 0016-5085, 2015, Volume 149, Issue 3, pp. 649 - 659
Background & Aims There are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients who have advanced liver disease. Methods... 
Gastroenterology and Hepatology | Liver Transplantation | Decompensated Cirrhosis | Hepatitis C Virus Infection | Fibrosing Cholestatic Hepatitis | C INFECTION | TRANSPLANTATION PATIENTS | RECIPIENTS | INTERFERON | THERAPY | ADEFOVIR DIPIVOXIL | CIRRHOSIS | GENOTYPE 1 INFECTION | OUTCOMES | GASTROENTEROLOGY & HEPATOLOGY | United States | Humans | Middle Aged | Fluorenes - therapeutic use | Liver Cirrhosis - mortality | Hepacivirus - genetics | Male | Cholestasis, Intrahepatic - drug therapy | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - mortality | Time Factors | Female | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Drug Therapy, Combination | Cholestasis, Intrahepatic - virology | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Liver Cirrhosis - drug therapy | Liver Cirrhosis - diagnosis | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Disease Progression | Cholestasis, Intrahepatic - mortality | Hepacivirus - enzymology | Liver Cirrhosis - virology | Cholestasis, Intrahepatic - diagnosis | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Drug Combinations | Care and treatment | Liver diseases | Hepatitis C virus | Hepatitis C | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2015, Volume 10, Issue 7, pp. e0133236 - e0133236
Serum levels of the interferon (IFN)-stimulated chemokine CXCL10 are increased during chronic HCV infection and associate with outcome of IFN-based therapy.... 
VIRUS-INFECTION | CHEMOKINES | MULTIDISCIPLINARY SCIENCES | CHRONIC HEPATITIS-C | PROTEIN-10 | GENOTYPE 1 INFECTION | PREDICTIVE-VALUE | RIBAVIRIN | INDUCTION | ASSOCIATION | SPONTANEOUS CLEARANCE | Recurrence | Interferons | Humans | Fluorenes - therapeutic use | Dipeptidyl Peptidase 4 - blood | Hepatitis C, Chronic - virology | Male | Adult | Female | Hepacivirus - physiology | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Virus Replication - drug effects | Chemokine CXCL10 - blood | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Dipeptidyl Peptidase 4 - genetics | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Convalescence | Chemokine CXCL10 - genetics | Protein Processing, Post-Translational | Hepatitis C, Chronic - genetics | Viral Load - drug effects | Infection | Care and treatment | Analysis | Interferon | Biological response modifiers | Hepatitis C virus | Health aspects | Therapy | Laboratories | Chronic infection | Critical care | Amino acids | Infections | Ribavirin | Clinical outcomes | Proteins | Genotype & phenotype | Hepatitis | Immunology | Hepatology | Post-translation | Pretreatment | Drug dosages | Genotypes | Statistical analysis | Liver diseases | Dendritic cells | Serum levels | Studies | Infectious diseases | CXCL10 protein | Biomarkers | Chemokines | Index Medicus | Virus Replication/drug effects | Viral Load/drug effects | Dipeptidyl Peptidase 4/blood | Dipeptidyl Peptidase 4/genetics | Chemokine CXCL10/blood | Hepatitis C, Chronic/blood | Life Sciences | Hepatitis C, Chronic/drug therapy | Hepatitis C, Chronic/virology | Hepatitis C, Chronic/genetics | Chemokine CXCL10/genetics | Benzimidazoles/therapeutic use | Hepacivirus/physiology | Fluorenes/therapeutic use | Antiviral Agents/therapeutic use | Sofosbuvir/therapeutic use | Hepacivirus/drug effects | Ribavirin/therapeutic use
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 146, Issue 3, pp. 736 - 743.e1
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 8, pp. 705 - 713
Among patients coinfected with HIV-1 and HCV genotype 1 or 4 who were receiving effective antiretroviral therapy, treatment with 12 weeks of ledipasvir and... 
MEDICINE, GENERAL & INTERNAL | HEPATOCELLULAR-CARCINOMA | INTERFERON | THERAPY | HEPATITIS-C VIRUS | CIRRHOSIS | ALPHA-2A PLUS RIBAVIRIN | VETERANS | GENOTYPE 1 INFECTION | COHORT | LIVER-DISEASE | HIV-1 | Humans | Middle Aged | Drug Resistance, Viral | Fluorenes - therapeutic use | Hepacivirus - genetics | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Viral Load | Female | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Fluorenes - pharmacokinetics | Hepacivirus - isolation & purification | Anti-Retroviral Agents - therapeutic use | Antiviral Agents - therapeutic use | Benzimidazoles - pharmacokinetics | Genotype | Hepatitis C, Chronic - drug therapy | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | HIV Infections - complications | HIV Infections - drug therapy | Uridine Monophosphate - pharmacokinetics | Sofosbuvir | Care and treatment | Research | Hepatitis C virus | HIV infection | Emtricitabine | Headache | Antiretroviral drugs | Inhibitor drugs | Diarrhea | Fatigue | Patients | Efavirenz | Studies | Tenofovir | Cirrhosis | Genotype & phenotype | Hepatitis | Human immunodeficiency virus--HIV | Hepatitis C | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 06/2017, Volume 64, Issue 12, pp. 1711 - 1720
Background. Large cohorts are needed to assess human immunodeficiency virus (HIV)/hepatitis C virus (HCV) real-world treatment outcomes. We examined the... 
real-world | HCV | HIV | DAA | INFECTIOUS DISEASES | HIV/HCV | LEDIPASVIR-SOFOSBUVIR | CHRONIC HEPATITIS-C | MICROBIOLOGY | COINFECTED INDIVIDUALS | IMMUNOLOGY | INFECTION | COHORT | Uridine Monophosphate - administration & dosage | Anilides - therapeutic use | Hepatitis C - drug therapy | Coinfection - drug therapy | Veterans | Humans | Middle Aged | Fluorenes - therapeutic use | Hepacivirus - genetics | Male | Carbamates - administration & dosage | Practice Patterns, Physicians | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Female | Fluorenes - administration & dosage | Hepatitis C - complications | Registries | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Administration, Oral | Antiviral Agents - therapeutic use | HIV Infections - virology | Ribavirin - therapeutic use | Genotype | Treatment Outcome | Antiviral Agents - administration & dosage | Coinfection - virology | Macrocyclic Compounds - therapeutic use | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | HIV Infections - complications | Hepatitis C - virology | HIV Infections - drug therapy | Aged | Macrocyclic Compounds - administration & dosage | Sustained Virologic Response | Carbamates - therapeutic use | Cohort Studies | Antiviral agents | Care and treatment